MedPath

Effectiveness of Laying-on-of-hands for Sickle Cell Disease

Phase 2
Completed
Conditions
Sickle Cell Disease
Death
Pain Crisis Recurrent
Anemia
Infection
Interventions
Behavioral: laying-on-of-hands
Registration Number
NCT01518218
Lead Sponsor
MOA Health Science Foundation
Brief Summary

The objective of this study is to evaluate the effectiveness of 1-year administration of laying-on-of-hands on the morbidity and mortality of patients with sickle cell disease in Africa.

Detailed Description

Patients with sickle cell disease (SCD) have a high risk of premature death in Africa, mainly due to insufficient medical services. SCD patients often visit emergency department and need hospitalization when they suffer from severe pain; however, they manage most of painful episodes at home. Appropriate pain management at home is, therefore, crucial to improve their clinical course and quality of life. Laying-on-of-hands may be a good candidate for home care management, because family member(s) can become a practitioner of laying-on-of-hands without difficulty and administer it to their loved one as an initial treatment whenever necessary. There are no reports concerning the effectiveness of laying-on-of-hands for the outcomes of SCD patients, as far as we have investigated.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria
  • patients with symptoms associated with sickle cell disease
  • those able to receive laying-on-of-hands every weekday for 1 year
  • those able to receive conventional medical treatment whenever necessary
  • those able to receive blood test at the beginning, after 6 month and after 1 year
Exclusion Criteria
  • those who wish to use other complementary and alternative therapies along with laying-on-of-hands

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
laying-on-of-handslaying-on-of-handsPatients of this arm received laying-on-of-hands twice a day (45 minutes each) every weekday for 1year, and received conventional medical treatment if necessary.
Primary Outcome Measures
NameTimeMethod
disease-related episodes and mortality3 years and 9 months
Secondary Outcome Measures
NameTimeMethod
blood data1 year

Trial Locations

Locations (1)

The national medical center for sickle cell disease

🇨🇩

Kinshasa, Congo, The Democratic Republic of the

© Copyright 2025. All Rights Reserved by MedPath